Anti-aging combination comprising lactobacillus sp. strain and fusion protein comprising CD80 protein and il-2 protein, and use thereof
A combination of CD80-IL-2 fusion protein and Lactobacillus sp. strain addresses age-related declines in muscle, immune, and intestinal functions, enhancing strength, immune function, and intestinal health.
Patent Information
- Application Number
- PCT/KR2026/005932
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-09-04
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current therapeutic strategies fail to comprehensively address the multifaceted decline in muscle function, immune function, and intestinal function associated with aging, including sarcopenia, immunosenescence, and intestinal structural abnormalities.
A combination therapy using a fusion protein comprising CD80 protein or its fragment and IL-2 protein or variant, alongside a Lactobacillus sp. strain, lysate, or culture medium, administered simultaneously, sequentially, or in any order, to target and improve these age-related declines.
The combination therapy effectively enhances muscle strength, restores immune function by increasing NK cells, and improves intestinal health by maintaining epithelial homeostasis and reducing inflammation, offering a comprehensive anti-aging effect.
Smart Images

Figure KR2026005932_12112026_PF_FP_ABST
Abstract
Description
Anti-aging combination comprising a strain of the genus Lactobacillus and a fusion protein containing CD80 protein and IL-2 protein, and uses thereof
[0001] The present invention relates to an anti-aging combination comprising a strain of the genus Lactobacillus and a fusion protein comprising CD80 protein and IL-2 protein, and the use thereof.
[0002] Aging is a complex biological process in which various physiological functions within the body gradually decline over time, involving structural and functional changes across various tissues and organs, such as reduced muscle function, decreased immune function, and intestinal dysfunction. As global population aging accelerates, there is a growing need for therapeutic approaches that can effectively prevent or improve age-related functional decline.
[0003] Age-related decline in muscle function is represented by sarcopenia. Characterized by a decrease in muscle mass along with a decline in muscle strength and motor function, sarcopenia is known as a major risk factor for age-related diseases as it is directly associated with falls, fractures, limited physical activity, and reduced quality of life in the elderly. Accordingly, maintaining or restoring muscle strength and motor function is receiving attention as one of the core goals of anti-aging treatment strategies.
[0004] Furthermore, aging leads to a decline in the overall function of the immune system, known as immunosenescence. Natural Killer (NK) cells, which are key cells of innate immunity, are known to decrease in number and function as aging progresses, which can lead to a decline in immune defense capabilities against infectious diseases and tumors. Therefore, restoring the proportion and function of NK cells in peripheral blood is considered an important indicator and therapeutic goal for improving immunosenescence.
[0005] Meanwhile, it has been reported that as aging progresses, changes in the composition of the gut microbiome are accompanied by the induction of a chronic low-grade inflammatory state, which can lead to the breakdown of intestinal epithelial homeostasis. According to previous studies, the maintenance and regeneration of intestinal stem cells are regulated by the Wnt signaling pathway and Lgr5 expression, and it has been reported that these signals decrease and stem cell function deteriorates with aging (Canonical Wnt Signaling Ameliorates Aging of Intestinal Stem Cells Nalapareddy et al., Cell Reports, 18(11):2608-2621, 2017). Furthermore, aging is known to induce microstructural changes in intestinal tissue, such as a decrease in the number of crypts per unit length while increasing the height and width of the crypts; this is understood to reflect regenerative imbalances and structural abnormalities in the intestinal epithelium. However, therapeutic strategies capable of effectively improving age-related decline in intestinal stem cell function and structural abnormalities in the intestine have not yet been clearly presented.
[0006] As such, although aging entails a complex decline in various biological functions, including muscle function, immune function, and intestinal function, no therapeutic strategy has been developed to date that can comprehensively improve these multifaceted aging-related functional declines. Therefore, there is an urgent need for the development of new approaches that can effectively prevent or treat the complex functional decline caused by aging.
[0007] One aspect provides a combination for anti-aging comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0008] Another aspect provides a pharmaceutical product comprising the above combination, which is administered simultaneously, sequentially, or in any order for an anti-aging effect.
[0009] Another aspect provides an anti-aging composition comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0010] Another aspect provides a combination for the prevention or treatment of diseases related to impaired intestinal function, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0011] Another aspect provides a pharmaceutical product comprising the above combination, which is administered simultaneously, sequentially, or in any order for the prevention or treatment of diseases related to impaired bowel function.
[0012] Another aspect provides a pharmaceutical composition for the prevention or treatment of diseases related to impaired intestinal function, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0013] Another aspect provides a combination for the prevention or treatment of age-related immune dysfunction, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0014] Another aspect provides a pharmaceutical product comprising the above combination, which is administered simultaneously, sequentially, or in any order for the prevention or treatment of age-related immune dysfunction.
[0015] Another aspect provides a pharmaceutical composition for the prevention or treatment of age-related immune dysfunction, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0016] Another aspect provides a combination for the prevention or treatment of sarcopenia-related diseases, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0017] Another aspect provides a pharmaceutical product comprising the above combination, which is administered simultaneously, sequentially, or in any order for the prevention or treatment of sarcopenia-related diseases.
[0018] Another aspect provides a pharmaceutical composition for the prevention or treatment of sarcopenia-related diseases, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0019] Another aspect provides an anti-aging composition comprising a first active substance for co-administration with a second active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0020] Another aspect provides an anti-aging composition comprising a second active substance to be administered in combination with a first active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0021] Another aspect provides a composition for the prevention or treatment of diseases related to impaired intestinal function comprising a first active substance to be administered in combination with a second active substance, wherein the first active substance comprises a fusion protein comprising CD80 protein or a fragment thereof and IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0022] Another aspect provides a composition for the prevention or treatment of diseases related to impaired intestinal function, comprising a second active substance to be administered in combination with a first active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0023] Another aspect provides a composition for the prevention or treatment of age-related immune function decline diseases comprising a first active substance to be administered in combination with a second active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0024] Another aspect provides a composition for the prevention or treatment of age-related immune function decline diseases comprising a second active substance to be administered in combination with a first active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0025] Another aspect provides a composition for the prevention or treatment of sarcopenia-related diseases comprising a first active substance to be administered in combination with a second active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0026] Another aspect provides a composition for the prevention or treatment of sarcopenia-related diseases comprising a second active substance to be administered in combination with a first active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0027] Another aspect provides an anti-aging combination therapy kit comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0028] Another aspect provides a combination therapy kit for the prevention or treatment of diseases related to impaired intestinal function, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0029] Another aspect provides a combination therapy kit for the prevention or treatment of age-related immune function decline, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0030] Another aspect provides a combination therapy kit for the prevention or treatment of sarcopenia-related diseases, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0031] Another aspect provides a use for manufacturing an anti-aging agent comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0032] Another aspect provides an anti-aging method comprising the step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
[0033] Another aspect provides an anti-aging method comprising: a step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to an individual in need thereof; and a step of administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
[0034] Another aspect provides the use of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof for use in anti-aging; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0035] Another aspect is to provide a use for the first active substance to be administered in combination with the second active substance for anti-aging purposes.
[0036] Another aspect is to provide a use for a second active substance to be administered in combination with a first active substance for anti-aging purposes.
[0037] Another aspect provides a use for a drug for the prevention or treatment of diseases related to impaired intestinal function, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0038] Another aspect provides a method for preventing or treating diseases related to impaired intestinal function, comprising the step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
[0039] Another aspect provides a method for treating a disease related to impaired intestinal function, comprising the steps of: administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to a person in need thereof; and administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to a person in need thereof.
[0040] Another aspect provides the use of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof for use in the prevention or treatment of diseases related to impaired bowel function; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0041] Another aspect is to provide a use of the first active substance for co-administration with the second active substance for the prevention or treatment of diseases related to impaired bowel function.
[0042] Another aspect is to provide a use for a second active substance to be administered in combination with a first active substance for the prevention or treatment of diseases related to impaired bowel function.
[0043]
[0044] Another aspect provides a use for manufacturing a drug for the prevention or treatment of age-related immune function decline diseases comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0045] Another aspect provides a method for preventing or treating age-related immune function decline, comprising the step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
[0046] Another aspect provides a method for treating age-related immune dysfunction, comprising the steps of: administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to a person in need thereof; and administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to a person in need thereof.
[0047] Another aspect provides the use of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof for use in the prevention or treatment of age-related immune dysfunction; and a second active substance comprising a Lactobacillus sp. strain, a lysate of the strain, a culture medium, or a mixture thereof.
[0048] Another aspect is to provide a use of the first active substance for co-administration with the second active substance for the prevention or treatment of age-related immune dysfunction.
[0049] Another aspect is to provide a use of a second active substance to be administered in combination with a first active substance for the prevention or treatment of age-related immune dysfunction.
[0050]
[0051] Another aspect provides a use for a drug for the prevention or treatment of sarcopenia-related diseases comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0052] Another aspect provides a method for preventing or treating sarcopenia-related diseases, comprising the step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
[0053] Another aspect provides a method for treating a sarcopenia-related disease comprising: a step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to a person in need thereof; and a step of administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to a person in need thereof.
[0054] Another aspect provides the use of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof for use in the prevention or treatment of sarcopenia-related diseases; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0055] Another aspect is to provide a use of the first active substance for co-administration with the second active substance for the prevention or treatment of sarcopenia-related diseases.
[0056] Another aspect is to provide a use of a second active substance for co-administration with a first active substance for the prevention or treatment of sarcopenia-related diseases.
[0057] One aspect provides an anti-aging combination comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0058] The term “combination” in this specification means two or more active substances intended to be used together for therapeutic purposes. It is not required that the active substances be mixed into a single formulation, and each active substance may be manufactured and provided independently in a separate formulation. Specifically, the combination includes each active substance being administered via the same or different routes of administration, and includes administration simultaneously, sequentially with a set time interval, or in any order. Furthermore, the dosage, frequency, and interval of administration of each active substance included in the combination may be determined independently of each other, and each active substance may be administered to achieve mutually complementary or synergistic therapeutic effects.
[0059] In one embodiment, the first active substance and the second active substance of the combination may be in separate formulations. For example, the first active substance may be provided as a parenteral formulation and the second active substance may be provided as an oral formulation, and for example, the first active substance may be provided as a subcutaneous formulation or an intravenous formulation, but is not limited thereto.
[0060] In one embodiment, the first active substance and the second active substance of the combination may be administered simultaneously, sequentially, or in any order.
[0061] One aspect provides a pharmaceutical product comprising the above combination, administered simultaneously, sequentially, or in any order for an anti-aging effect.
[0062] The term “pharmaceutical product” in this specification means a formulation or a set of formulations comprising one or more active substances, intended to be used together for a specific therapeutic or preventive purpose. The pharmaceutical product is not limited to being provided as a single formulation, but includes two or more active substances provided in separate formulations, packaged or directed to be administered together, simultaneously, sequentially, or in any order. Specifically, the pharmaceutical product may be provided in a form that includes separate containers containing each active substance and instructions or leaflets regarding co-administration.
[0063]
[0064] One aspect provides an anti-aging composition comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0065] The term “CD80 protein” in this specification refers to a membrane protein expressed in dendritic cells, activated B cells, and monocytes, also referred to as “B7-1”. CD80 provides a co-stimulatory signal essential for the activation and survival of T cells and functions as a ligand for CD28 and CTLA-4 expressed on the surface of T cells. The CD80 protein is composed of 288 amino acids and, in one embodiment, may include the amino acid sequence of SEQ ID NO. 2, but is not limited thereto. Additionally, the CD80 protein may include variants having sequence identity of 70% or more, 80% or more, 90% or more, or 95% or more with the sequence and exhibiting equivalent biological activity.
[0066] The term "CD80 fragment" in this specification refers to a truncated form consisting of a portion of the amino acid sequence of the CD80 protein. In one embodiment, the CD80 fragment may include, but is not limited to, the extracellular domain of CD80, and is interpreted to include any fragment as long as it possesses the biological activity of CD80, namely, the ability to bind to CD28 or CTLA-4.
[0067] In one embodiment, the fragment of the CD80 protein may have the amino acid sequence of SEQ ID NO. 3, but is not limited thereto.
[0068] In this specification, the terms “IL-2” or “interleukin-2” refer to a cytokine that induces the proliferation, differentiation, and activation of T cells and natural killer (NK) cells. The IL-2 may include, but is not limited to, wild-type IL-2 of any vertebrate origin, variants thereof, and proteins having substantially equivalent biological activity.
[0069] In one embodiment, the IL-2 may have the amino acid sequence of SEQ ID NO. 8, but is not limited thereto.
[0070] In this specification, the term "IL-2 fragment" refers to a truncated form consisting of a portion of the amino acid sequence of the full-length IL-2 protein. The IL-2 fragment is not limited in length or position as long as it retains the biological activity of wild-type IL-2, i.e., specific binding ability to the IL-2 receptor, and can be prepared by methods known in the art.
[0071] The term "IL-2 variant" in this specification refers to a form in which one or more amino acid sequences of full-length IL-2 or an IL-2 fragment are substituted, and includes proteins having an amino acid sequence different from wild-type IL-2 or a fragment thereof, but possessing biological activity equivalent to or similar to that of wild-type IL-2. In this specification, "IL-2 activity" refers to the ability to specifically bind to an IL-2 receptor, which can be measured by methods known in the art.
[0072] The amino acid introduced by the above substitution may be any one selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine, but is not limited thereto.
[0073] In one embodiment, the IL-2 variant may be one in which one or more amino acids selected from the group consisting of the 38th, 42nd, 45th, 61st, and 72nd amino acids in the amino acid sequence of SEQ ID NO. 8 are substituted with other amino acids, but is not limited thereto.
[0074] In one embodiment, the IL-2 variant (hIL2v3) may be a triple variant based on a wild-type IL-2 having the amino acid sequence of SEQ ID NO. 8, comprising R38A and F42A substitutions, into which an additional single amino acid substitution is introduced.
[0075] For example, the above IL-2 variant (hIL2v3) may be hIL2v3 M45 having the amino acid sequence of SEQ ID NO. 9 with an additional Y45A substitution introduced to the above double variant, hIL2v3 M61 having the amino acid sequence of SEQ ID NO. 10 with an additional E61R substitution introduced, or hIL2v3 M72 having the amino acid sequence of SEQ ID NO. 11 with an additional L72G substitution introduced, but is not limited thereto.
[0076] In one embodiment, the IL-2 variant (hIL2v3) may have the amino acid sequence of SEQ ID NO. 10.
[0077] In this specification, IL-2 or variants thereof are collectively referred to as "IL-2 protein" or "IL-2 polypeptide." IL-2, IL-2 protein, IL-2 polypeptide, and IL-2 variants specifically bind to, for example, an IL-2 receptor. This specific binding can be verified by methods known to those skilled in the art.
[0078] The terms “linker” or “carrier” in this specification refer to an amino acid sequence or protein domain that connects two protein domains, and the two terms may be used interchangeably in this specification. In one embodiment, the linker may include a sequence of 1 to 50 amino acids, albumin or a fragment thereof, or the Fc domain of an immunoglobulin.
[0079] The term “Fc domain of immunoglobulin” in this specification refers to a protein domain comprising the heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) of immunoglobulin, and excluding the variable regions of the heavy and light chains and the light chain constant region 1 (CH1) of immunoglobulin. The immunoglobulin may be IgG, IgA, IgE, IgD, or IgM, and in one embodiment may be IgG4. For example, the Fc domain of wild-type IgG4 may comprise the amino acid sequence of SEQ ID NO. 5, but is not limited thereto.
[0080] In one embodiment, the Fc domain of the immunoglobulin may be a wild-type Fc domain as well as an Fc domain variant.
[0081] The term "Fc domain variant" in this specification refers to a form having a glycosylation pattern different from that of the wild-type Fc domain, and includes all forms with increased glycosylation, decreased glycosylation, deglycosylated, or aglycosylated forms compared to the wild-type Fc domain. The Fc domain variant may have the number of sialic acids, the degree of fucosylation, or the glycosylation pattern adjusted through the regulation of culture conditions or genetic manipulation of host cells, but is not limited thereto.
[0082] In one embodiment, the fusion protein may refer to a single polypeptide chain in which the CD80 protein or a fragment thereof and the IL-2 protein or a variant thereof are linked by a linker. For example, the IL-2 or a variant thereof and the CD80(B7-1) or a fragment thereof may be joined by a linker. In one embodiment, the linker may be an IgG4 Fc domain. For example, the IgG4 Fc domain may be SEQ ID NO. 5 or SEQ ID NO. 6, but is not limited thereto.
[0083] In one embodiment, the fusion protein may comprise a structure in which the extracellular domain amino acid sequence of human CD80, the hinge sequence, the IgG4 Fc domain variant sequence, the linker sequence, and the IL-2 variant (hIL2v3) sequence are sequentially connected from the N-terminus to the C-terminus.
[0084] In one embodiment, the fusion protein may comprise a structure in which the amino acid sequence of SEQ ID NO. 3, which is the extracellular domain of human CD80 (fragment of human CD80), the hinge sequence of SEQ ID NO. 4, the IgG4 Fc domain variant sequence of SEQ ID NO. 6, the linker sequence of SEQ ID NO. 7, and the IL-2 variant (hIL2v3) sequence of SEQ ID NO. 10 are sequentially connected from the N-terminus to the C-terminus.
[0085] In one embodiment, the fusion protein may include the amino acid sequence of SEQ ID NO. 12, but is not limited thereto.
[0086] The term "dimer" in this specification refers to a complex formed by the combination of two molecules of the fusion protein. In one embodiment, the dimer may be formed by a disulfide bond between cysteine residues present in the linker, but is not limited thereto. For example, the two fusion proteins constituting the dimer may be identical or different, and in one embodiment, may be homodimers.
[0087] In one embodiment, as shown in FIG. 1, the fusion protein may have a dimeric form including an IgG4 Fc domain, and each monomer may include a CD80(B7-1) domain, an IgG4 Fc domain, and an IL-2 variant. Specifically, the CD80(B7-1) domain may be located at the N-terminal side of each monomer, the IL-2 variant may be located at the C-terminal side of each monomer, and the IgG4 Fc domain may be located as a region mediating the dimerization of the two monomers, but is not limited thereto.
[0088] The term "Lactobacillus sp. strain" in this specification refers to a microorganism belonging to the aerobic or facultative anaerobic gram-positive bacillus that is widely distributed in nature, and is not limited to any type of Lactobacillus sp. strain known in the art.
[0089] In one embodiment, the Lactobacillus strain is Lactobacillus sakei, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus delbrueckii, Lactobacillus johnsonii, and Lactobacillus It may be one or more selected from the group consisting of *Lactobacillushelveticus*, but is not limited thereto.
[0090] As used in this specification, "Lactobacillus sp." refers to the old genus of Lactobacillus prior to reclassification based on recent phylogenetic analysis, and is interpreted to include Lactiplantibacillus and LimosiLactobacillus, whose names were changed following the reclassification. Specifically, Lactobacillus fermentum was changed to LimosiLactobacillus fermentum, and Lactobacillus plantarum was changed to Lactiplantibacillus plantarum. In this specification, the strain names before and after the change have been used interchangeably.
[0091] The term "Lactobacillus fermentum GB102 strain" in this specification refers to a strain comprising a 16S rRNA gene consisting of the nucleotide sequence of SEQ ID NO. 13. In one embodiment, the GB102 strain may be a strain comprising a 16S rRNA gene having at least 93%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, 99.9%, or 100% sequence identity with the nucleotide sequence of SEQ ID NO. 13, and may be a strain deposited under accession number KCTC 14105BP. The above GB102 strain includes naturally occurring mutants and can be used in the form of viable cells, dead cells, or a cytoplasmic fraction obtained by lysing the strain, preferably in the form of viable cells, but is not limited thereto.
[0092] The term "Lactobacillus fermentum GB103 strain" in this specification refers to a strain comprising a 16S rRNA gene consisting of the nucleotide sequence of SEQ ID NO. 14. In one embodiment, the GB103 strain may be a strain comprising a 16S rRNA gene having at least 93%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, 99.9%, or 100% sequence identity with the nucleotide sequence of SEQ ID NO. 14, and may be a strain deposited under accession number KCTC 14106BP. The GB103 strain may include naturally occurring mutants and may be used in the form of live cells, dead cells, or cytoplasmic fractions obtained by lysing the strain, and preferably may be in the form of live cells, but is not limited thereto.
[0093] The term "Lactobacillus plantarum GB104 strain" in this specification refers to a strain comprising a 16S rRNA gene consisting of the nucleotide sequence of SEQ ID NO. 15. In one embodiment, the GB104 strain may be a strain comprising a 16S rRNA gene having at least 93%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.8%, 99.9%, or 100% sequence identity with the nucleotide sequence of SEQ ID NO. 15, and may be a strain deposited under accession number KCTC 14107BP. The GB104 strain may include naturally occurring mutants and may be used in the form of live cells, dead cells, or cytoplasmic fractions obtained by lysing the strain, and preferably may be in the form of live cells, but is not limited thereto.
[0094] In one embodiment, the Lactobacillus strain may be one or more of the Lactobacillus fermentum GB102 strain deposited at KCTC 14105BP, the Lactobacillus fermentum GB103 strain deposited at KCTC 14106BP, and the Lactobacillus plantarum GB104 strain deposited at KCTC 14107BP.
[0095] In this specification, the term "culture" may be used interchangeably with "culture medium," "culture supernatant," "culture supernatant," "conditional culture medium," or "conditioning medium," and may refer to the entire medium containing said strain, said metabolites, excess nutrients, etc., obtained by culturing said strain for a certain period in a medium capable of supplying nutrients so that said Lactobacillus plantarum strain can grow and survive in a test tube. For example, said culture may refer to a product obtained by culturing said Lactobacillus plantarum strain in a known medium, and said product may or may not include the strain itself. said medium may be selected from known liquid or solid media, and may be, for example, MRS liquid medium, GAM liquid medium, MRS agar medium, GAM agar medium, BL agar medium, but is not limited thereto. The above culture may include the culture medium itself, its concentrate, or freeze-dried product obtained by culturing the strain, or the culture supernatant, its concentrate, or freeze-dried product obtained by removing the strain from the culture medium.
[0096] In this specification, the term “lysate” may be used interchangeably with “lysate,” which refers to a solution or suspension in an aqueous medium of broken cells of microorganisms, such as Lactobacillus plantarum. Cell lysates comprise macromolecules, such as DNA, RNA, proteins, peptides, carbohydrates, lipids, etc., and / or micromolecules, such as amino acids, sugars, fatty acids, etc., or fractions thereof. Additionally, said lysates comprise cell debris that may have a smooth or granular structure.
[0097] In one embodiment, the second active substance may comprise the Lactobacillus fermentum GB102 strain deposited at KCTC 14105BP, the Lactobacillus fermentum GB103 strain deposited at KCTC 14106BP, and the Lactobacillus plantarum GB104 strain deposited at KCTC 14107BP.
[0098] In one embodiment, the second active substance may further include red ginseng or a vitamin.
[0099] The term “red ginseng” in this specification refers to fresh ginseng processed through steaming and drying processes, containing various ginsenoside components generated during the processing. The ginsenosides are the main physiologically active components of red ginseng and are known to exhibit immune-modulating, anti-inflammatory, antioxidant, and anti-aging effects. In one embodiment, the red ginseng may contain one or more ginsenosides selected from the group consisting of ginsenosides Rg1, Rb1, and Rg3, but is not limited thereto. The above ginsenosides Rg1 and Rb1 are representative protopanaxatriol and protopanaxadiol ginsenosides of red ginseng, respectively, and are known to promote the activation and proliferation of immune cells, while ginsenoside Rg3 is a red ginseng-specific component generated during the steaming process and is known to exhibit anti-inflammatory and immunomodulatory effects.
[0100] The term "vitamin" in this specification refers to an organic micronutrient essential for maintaining normal physiological functions within the body, and includes substances that are not synthesized internally or whose synthesized amounts are insufficient and therefore require supply from external sources. Vitamins can be classified into fat-soluble vitamins and water-soluble vitamins. Fat-soluble vitamins include vitamins A, D, E, and K, while water-soluble vitamins include the B vitamins (B1, B2, B3, B5, B6, B7, B9, B12) and vitamin C.
[0101] In one embodiment, the vitamin may be one or more selected from the group consisting of vitamin A, vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine), vitamin B7 (biotin), vitamin B9 (folic acid), vitamin B12 (cobalamin), vitamin C (ascorbic acid), vitamin D, vitamin E, and vitamin K, but is not limited thereto.
[0102] In one embodiment, the vitamin may be vitamin B2 (riboflavin), but is not limited thereto. Vitamin B2 is a water-soluble vitamin involved in energy metabolism, cell growth, and redox reactions, and is known to play an important role in the growth and maintenance of function of intestinal microorganisms.
[0103] The term "GIB-7" in this specification refers to the same composition as "Number Seven," "NO. 7," "#7," "GI Long Jebity Number Seven," "GI Long Jebity #7," and "GI Long Jebity Number Seven," and is used interchangeably throughout this specification.
[0104] In one embodiment, the above GIB-7 may refer to a complex composition comprising a Lactobacillus strain, red ginseng, and vitamins. In one embodiment, the above Lactobacillus strain may include one or more of the Lactobacillus fermentum GB102 strain deposited under deposit number KCTC 14105BP, the Lactobacillus fermentum GB103 strain deposited under deposit number KCTC 14106BP, and the Lactobacillus plantarum GB104 strain deposited under deposit number KCTC 14107BP, and preferably may include all three strains.
[0105] In one embodiment, the red ginseng may include ginsenosides Rg1, Rb1, and Rg3, and the vitamin may be vitamin B2 (riboflavin), but is not limited thereto.
[0106] In one embodiment, the second active substance may mean GIB-7.
[0107] The term “anti-aging” in this specification refers to any action that prevents, inhibits, or improves various physiological functions in vivo that gradually decline with aging. Since aging involves complex structural and functional changes across various tissues and organs, such as muscle decline, immune decline, and intestinal dysfunction, the term “anti-aging” in this specification is used as a concept that encompasses actions that comprehensively prevent or improve these multifaceted declines in aging-related functions.
[0108] In one embodiment, the anti-aging may include the improvement of muscle strength and motor function. Specifically, the anti-aging may include restoring grip strength that has declined with aging or inhibiting the progression of sarcopenia, but is not limited thereto.
[0109] In one embodiment, the anti-aging effect may include the improvement of immune function. Specifically, the anti-aging effect may increase the proportion of natural killer (NK) cells in peripheral blood that has decreased with aging, or restore the function of lymphocytes, but is not limited thereto.
[0110] In one embodiment, the anti-aging may include the improvement of intestinal function. Specifically, the anti-aging may normalize the length of the intestine increased with aging, restore the expression of intestinal stem cell-related genes, and maintain intestinal epithelial homeostasis, but is not limited thereto.
[0111] In one embodiment, the anti-aging may include the inhibition of intestinal inflammation. Specifically, the anti-aging may reduce the expression of inflammatory cytokines that increase with aging and improve chronic low-grade inflammation in the intestines, but is not limited thereto.
[0112] In one embodiment, the anti-aging may include one or more selected from the group consisting of improvement of muscle function, improvement of immune function, and improvement of intestinal function, but is not limited thereto.
[0113] In one embodiment, the anti-aging may include the prevention or treatment of one or more diseases selected from the group consisting of diseases related to intestinal dysfunction, diseases related to decreased immune function, and diseases related to sarcopenia, but is not limited thereto.
[0114] In one embodiment, the anti-aging may include one or more of the following characteristics, but is not limited thereto:
[0115] - Improvement in one or more muscle functions selected from the group consisting of grip strength, knee extension strength, and gait ability,
[0116] - One or more improvements in immune function selected from the group consisting of an increase in the number or proportion of natural killer (NK) cells in peripheral blood, an increase in the NK / regulatory T cell (Treg) ratio, and recovery of lymphocyte function; and
[0117] - One or more improvements in intestinal function selected from the group consisting of a reduction in small intestine length increased by aging, increased expression of intestinal stem cell markers, decreased expression of inflammatory cytokines, and maintenance of intestinal epithelial homeostasis.
[0118]
[0119] Another aspect provides a combination for the prevention or treatment of diseases related to impaired intestinal function, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0120] Another aspect provides a pharmaceutical product comprising the above combination, which is administered simultaneously, sequentially, or in any order for the prevention or treatment of diseases related to impaired bowel function.
[0121] Another aspect provides a pharmaceutical composition for the prevention or treatment of diseases related to impaired intestinal function, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0122] The term “diseases related to intestinal dysfunction” in this specification is used as a concept encompassing diseases associated with a state in which the normal digestive, absorption, immune, and barrier functions of the intestines are impaired or damaged due to structural or functional abnormalities of the intestinal epithelium, reduced function of intestinal stem cells, increased intestinal inflammatory response, or changes in the intestinal microbial environment. Such intestinal dysfunction may be caused by aging, inflammation, infection, immune abnormalities, or other pathological causes, and may be accompanied by clinical manifestations such as reduced intestinal motility, decreased efficiency of nutrient absorption, breakdown of intestinal epithelial homeostasis, and intestinal dysbiosis.
[0123] In one embodiment, the disease related to bowel dysfunction may be one or more selected from the group consisting of inflammatory bowel disease, irritable bowel syndrome, reduced intestinal epithelial regeneration, intestinal atrophy, leaky gut syndrome, and age-related bowel dysfunction, but is not limited thereto.
[0124]
[0125] Another aspect provides a combination for the prevention or treatment of age-related immune dysfunction, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0126] Another aspect provides a pharmaceutical product comprising the above combination, which is administered simultaneously, sequentially, or in any order for the prevention or treatment of age-related immune dysfunction.
[0127] Another aspect provides a pharmaceutical composition for the prevention or treatment of age-related immune function decline diseases, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0128] The term “age-related immune dysfunction” in this specification is used as a concept encompassing diseases associated with a state in which the normal functions of innate immunity and adaptive immunity are impaired or compromised due to the overall decline in immune system function associated with aging, known as immunosenescence. As aging progresses, there is a decrease in the number and function of immune cells, including natural killer (NK) cells, T cells, and B cells, which can lead to a decline in immune defense capabilities against infections, tumors, and chronic inflammation. Furthermore, the chronic low-grade inflammation (inflammaging) induced by aging is known to disrupt the homeostasis of the immune system, thereby promoting the onset and progression of various age-related diseases.
[0129] In one embodiment, the aging-related immune function decline disease may be one or more selected from the group consisting of immunosenescence, natural killer (NK) cell dysfunction, aging-related infection vulnerability, aging-related chronic low-grade inflammation, aging-related cancer surveillance decline, aging-related viral infection, and aging-related vaccine response decline, but is not limited thereto.
[0130] In one embodiment, the aging-related immune function decline disease may be one or more selected from the group consisting of NK cell deficiency, herpes zoster, influenza infection, sepsis, tuberculosis and aging-related malignant tumors, but is not limited thereto.
[0131]
[0132] Another aspect provides a combination for the prevention or treatment of sarcopenia-related diseases, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0133] Another aspect provides a pharmaceutical product comprising the above combination, which is administered simultaneously, sequentially, or in any order for the prevention or treatment of sarcopenia-related diseases.
[0134] Another aspect provides a pharmaceutical composition for the prevention or treatment of sarcopenia-related diseases, comprising: a first active substance comprising a fusion protein comprising a variant in the group consisting of CD80 protein or a fragment thereof and IL-2 protein or thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0135] The term “muscle aging” in this specification means that the density and function of muscles gradually weaken as mitochondria within muscle fibers lose their activity or the number of mitochondria decreases due to aging, and may refer to muscle loss-related diseases including sarcopenia.
[0136] The term "sarcopenia-related disease" in this specification refers to a disease caused by the progressive weakening of muscle density and function due to a decrease in the activity or number of mitochondria within muscle fibers as a result of aging.
[0137] In one embodiment, the sarcopenia-related disease may be one or more selected from the group consisting of sarcopenia, senile sarcopenia, atony, muscular atrophy, muscular dystrophy, disuse muscle atrophy, motor neuron disease, inflammatory myopathy, neuromuscular junction disease, endocrine myopathy, muscle degeneration, myosynovitis, amyotrophic lateral sclerosis, myasthenia gravis, myositis, muscle calcification, muscle ossification, and muscle weakness-related diseases, but is not limited thereto. The sarcopenia-related disease may be accompanied by muscle inflammation due to trauma, and the composition of the present invention has the effect of alleviating or improving muscle inflammation.
[0138] The term "pharmaceutical composition" in this specification means a formulation comprising one or more active ingredients and pharmaceutically acceptable carriers or excipients for purposes such as specific treatment, prevention, or diagnosis. A pharmaceutical composition includes both forms: (i) a single formulation comprising a first active substance and a second active substance within a single formulation, or (ii) a first formulation comprising the first active substance and a second formulation comprising the second active substance, each independently formulated to be administered to a patient simultaneously, sequentially, or in any order.
[0139] In one embodiment, the pharmaceutical composition according to the form of (ii) may be provided such that the first formulation and the second formulation are contained in separate containers, and may further include instructions for use containing information regarding the order of administration, the interval of administration, and / or the dosage, as needed.
[0140] The first formulation containing the first active substance may be formulated as a parenteral formulation. Specifically, it may be formulated as an intravenous formulation (IV) or a subcutaneous formulation (SC), and may be prepared in the form of a sterile aqueous solution, a non-aqueous solvent, a suspension, an emulsion, or a lyophilized formulation. As a non-aqueous solvent or suspension, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, etc. may be used. In addition, to increase stability or absorption, carbohydrates such as glucose, sucrose, or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, or stabilizers may be included. The first active substance is administered in a pharmaceutically effective amount. The effective dose level may be determined based on factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field. In one embodiment, the first active substance may be administered at a dose of 0.005 mg / kg to 100 mg / kg, specifically 0.01 mg / kg to 10 mg / kg. In one embodiment, the first active substance may be administered intravenously at 4-week intervals (Q4W), but is not limited thereto.
[0141] The second formulation containing the second active substance may be formulated into an oral formulation. Solid formulations for oral administration may include tablets, pills, powders, granules, capsules, etc., and liquid formulations for oral administration may include suspensions, liquid formulations, emulsions, syrups, etc. The formulation may include a pharmaceutically acceptable diluent or carrier, and the diluent may include lactose, corn starch, soybean oil, microcrystalline cellulose, or mannitol. Excipients, disintegrants, binders, or lubricants may be used as carriers, and microcrystalline cellulose, lactose, or low-substituted hydroxycellulose may be used as excipients; calcium carboxymethylcellulose, sodium starch glycolate, or calcium monohydrogen phosphate may be used as disintegrants; polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, or hydroxypropylcellulose may be used as binders; and magnesium stearate, silicon dioxide, or talc may be used as lubricants.
[0142] The second active substance is administered in a pharmaceutically effective amount. The strain is included in the composition in a therapeutically effective amount, for example, 10³ to 10 16 It may be included at a content of CFU / g. The dosage of Lactobacillus strains may be 0.01 mg to 10,000 mg, and for adult patients, 1×10³ to 1×10 16 Live or dead bacteria of CFU / g may be administered in a single dose or in multiple doses. In one embodiment, the second active substance may be administered orally once a day, but is not limited thereto. The dosage may be prescribed in various ways depending on factors such as the formulation method, method of administration, patient's age, body weight, gender, pathological condition, food, time of administration, route of administration, excretion rate, and response responsiveness, and a person skilled in the art can appropriately adjust the dosage by taking these factors into consideration.
[0143] The first formulation containing the first active substance and the second formulation containing the second active substance may be administered at the same time or sequentially at different times, and the order of administration, time of administration, route of administration, interval of administration, and / or number of administrations may vary depending on various factors and similar factors well known in the pharmaceutical field, including the type of individual, age, weight, general health condition, symptoms or severity of disease, gender, diet, excretion, and components of drugs or other compositions used together with the individual at the same time or at different times. Furthermore, regarding the type and degree of response to be achieved by administration, a person skilled in the art can easily determine and prescribe the dosage of each active substance effective for the intended treatment. Therefore, the above dosage does not limit the scope of the present invention in any way.
[0144] The term "pharmaceuticalally effective amount" in this specification means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including the type and severity of the patient's disease, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field.
[0145] In this specification, the term "administration" means introducing a specific substance into an individual by an appropriate method, and said individual refers to any living organism, including humans, rats, mice, livestock, etc., that may possess anti-aging related diseases, sarcopenia-related diseases, or symptoms related thereto. Specifically, it may be a mammal, including humans, and may be, for example, a person, cattle, horses, pigs, dogs, sheep, goats, or cats, but is not limited thereto.
[0146] In this specification, the term "treat" means inhibiting the progression of a stress-related disorder or disease, reducing its severity, or improving, alleviating, or reducing one or more symptoms caused by said disorder.
[0147] In this specification, the term "prevention" refers to a method of partially or completely delaying or preventing the onset or recurrence of a disease, disorder, or its associated symptoms, preventing the acquisition or reacquisition of a disease or disorder, or reducing the risk of acquiring a disease or disorder. For example, the above prevention refers to any act of suppressing or delaying the occurrence of a stress-related disorder or disease by administering a composition according to the present invention.
[0148]
[0149] Another aspect provides an anti-aging composition comprising a first active substance for co-administration with a second active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0150] Another aspect provides an anti-aging composition comprising a second active substance to be administered in combination with a first active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0151] Another aspect provides an anti-aging composition comprising a first active substance to be administered in combination with a second active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof, for the prevention or treatment of diseases related to intestinal dysfunction.
[0152] Another aspect provides an anti-aging composition comprising a second active substance to be administered in combination with a first active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof, for the prevention or treatment of diseases related to intestinal dysfunction.
[0153] Another aspect provides an anti-aging composition comprising a first active substance to be administered in combination with a second active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof, for the prevention or treatment of age-related immune function decline.
[0154] Another aspect provides an anti-aging composition comprising a second active substance to be administered in combination with a first active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof, for the prevention or treatment of age-related immune function decline.
[0155] Another aspect provides an anti-aging composition comprising a first active substance to be administered in combination with a second active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof, for the prevention or treatment of sarcopenia-related diseases.
[0156] Another aspect provides an anti-aging composition comprising a second active substance to be administered in combination with a first active substance, wherein the first active substance comprises a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof, and the second active substance comprises a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof, for the prevention or treatment of sarcopenia-related diseases.
[0157] Another aspect provides a method for preventing or treating diseases related to impaired intestinal function, comprising the step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
[0158] Another aspect provides an anti-aging method comprising: a step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to an individual in need thereof; and a step of administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
[0159] Another aspect provides a method for treating a disease related to impaired intestinal function, comprising the steps of: administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to a person in need thereof; and administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to a person in need thereof.
[0160] Another aspect provides a method for treating age-related immune dysfunction, comprising the steps of: administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to a person in need thereof; and administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to a person in need thereof.
[0161] Another aspect provides a method for treating a sarcopenia-related disease comprising: a step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to a person in need thereof; and a step of administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to a person in need thereof.
[0162] In this specification, the terms “concurrent administration,” “concurrent therapy,” or “in combination” refer to any form of simultaneous or concurrent treatment using at least two distinct therapeutic agents. The components of the combination therapy may be administered simultaneously, sequentially, or in any order. The components may be administered in an appropriate manner at different dosages, at different frequencies of administration, or through different routes.
[0163] Specifically, the combined administration may involve administering the first active substance and the second active substance simultaneously, or administering one first and then sequentially administering the other. In one embodiment, the first active substance may be administered by subcutaneous injection or intravenous injection, and the second active substance may be administered by oral administration, but is not limited thereto.
[0164] A combination therapy according to the present invention may be defined as providing a synergistic effect if, for example, the efficacy measured through the degree of response, the rate of response, the time to disease progression, or the survival period is therapeutically superior to the efficacy that can be obtained by administering one or the rest of the components of the combination therapy at a normal dose.
[0165] Specifically, it may be defined as providing a synergistic effect when the anti-aging effect, including improvement in muscle strength, improvement in immune function, and improvement in intestinal function, is superior compared to when the first active substance or the second active substance is administered alone. Specifically, when the efficacy obtained when administered in combination is therapeutically superior to the efficacy obtained when using the first active substance and the second active substance individually, the combination administration is considered to exhibit a synergistic effect. In particular, a synergistic effect is considered to exist when equivalent or superior anti-aging effects can be achieved while reducing side effects that may occur when each active substance is administered alone at a normal dose, or when therapeutic effects, including improvement in muscle strength, increase in NK cell ratio, and normalization of intestinal function, can be maintained or enhanced while reducing the dosage of each active substance.
[0166] In this specification, the term “simultaneously administered” is not particularly limited and means that the components of a combination therapy are administered substantially simultaneously, for example, as a mixture or in an immediately following order.
[0167] In this specification, the term “sequentially administered” is not particularly limited and means that the components of the combination therapy are not administered simultaneously, but are administered one by one or in groups with specific time intervals between administrations. The time intervals between each administration of the components of the combination therapy may be the same or different and may be selected, for example, from 2 minutes to 96 hours, 1 day to 7 days, or 1 week, 2 weeks, or 3 weeks. Generally, the time interval between administrations may be in the range of minutes to hours, for example, 2 minutes to 72 hours, 30 minutes to 24 hours, or 1 to 12 hours. Additional examples include time intervals in the range of 24 to 96 hours, 12 to 36 hours, 8 to 24 hours, and 6 to 12 hours.
[0168] The term "therapeutically effective amount" in this specification refers to an amount of the pharmaceutical composition of the present invention, namely the first active substance (GI-102) and / or the second active substance (GIB-7), administered by a researcher, physician, or other clinician to elicit a biological or medical response or a desired therapeutic effect in a patient. Specifically, the therapeutically effective amount may mean an amount sufficient to produce one or more of the following effects: improvement of age-related muscle weakness, increase in the proportion of natural killer (NK) cells in peripheral blood, normalization of intestinal length, and restoration of intestinal stem cell-related gene expression.
[0169] The above therapeutic effective dose may vary depending on factors such as the individual's disease state, age, sex and body weight, route of administration, frequency and duration of administration, and the ability of each active substance to elicit a desired response in the individual. Furthermore, the above therapeutic effective dose must be determined as an amount in which the therapeutically beneficial effect outweighs the toxic or harmful effect.
[0170]
[0171] Another aspect provides an anti-aging combination therapy kit comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0172] Another aspect provides a combination therapy kit for the prevention or treatment of diseases related to intestinal dysfunction, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0173] Another aspect provides a combination therapy kit for the prevention or treatment of age-related immune dysfunction, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0174] Another aspect provides a combination therapy kit for the prevention or treatment of sarcopenia-related diseases, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0175]
[0176] In the above kit, the definitions regarding the “fusion protein,” “GIB-7,” “Lactobacillus strain,” “anti-aging,” etc. are as described above.
[0177] The term “kit” in this specification refers to a product form that provides two or more active substances together to exhibit an anti-aging effect. The kit may be provided in a form for administering a first active substance and a second active substance simultaneously, sequentially, or separately, and each active substance may be contained in the same container or in separate containers. The kit may additionally include instructions regarding the method of administration, the order of administration, the dosage, etc., of each active substance.
[0178] In one embodiment, the kit may include separate containers each containing the first active substance and the second active substance.
[0179]
[0180] Another aspect provides a feed combination for anti-aging of animals comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
[0181] In the above feed combination, the definitions regarding the “combination,” “fusion protein,” “GIB-7,” “Lactobacillus strain,” “anti-aging,” etc. are as previously stated.
[0182] The term "feed combination" in this specification refers to a combination comprising two or more active substances that is fed to animals for the purpose of providing nutrition, maintaining health, or preventing or improving age-related functional decline. The active substances included in the feed combination may be mixed as a single formulation or provided in a separated state as separate formulations, and may be fed simultaneously, sequentially, or separately.
[0183] In one embodiment, the first active substance and the second active substance may each be administered or supplied via different administration routes.
[0184] In one embodiment, the first active substance may be administered via a parenteral route. The parenteral administration includes, but is not limited to, intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, epidural, or intrasternal injection or infusion. Preferably, the first active substance may be administered by intravenous (IV) injection or IV infusion.
[0185] In one embodiment, the second active substance may be administered via an oral route. The oral administration may include, but is not limited to, a complete feed, a supplementary feed, a functional feed, a concentrate feed, a powder, pellets, granules, a liquid, or a mixture thereof.
[0186] For example, the first active substance may be administered by intravenous injection and the second active substance may be fed orally, but is not limited thereto. Specifically, the first active substance may be administered by a parenteral route such as intravenous injection, and the second active substance may be fed in the form of a complete feed, supplementary feed, functional feed, concentrate feed, powder, pellet, granule, liquid, or a mixture thereof.
[0187] In one embodiment, the first active substance and the second active substance may be administered or supplied simultaneously, sequentially, or separately.
[0188] In one embodiment, the second active substance may additionally include red ginseng and a vitamin in addition to a strain of the genus Lactobacillus. Specifically, the red ginseng may include ginsenosides Rg1, Rb1, and Rg3, and the vitamin may be vitamin B2 (riboflavin), but is not limited thereto.
[0189] The above feed combination may be used to prevent or improve age-related functional decline, including but not limited to muscle weakness, decreased immune function, and decreased intestinal function due to aging.
[0190] The above feed mixture may be applied to livestock, companion animals, laboratory animals, or other non-human animals. For example, the companion animals may include, but are not limited to, dogs, cats, rabbits, hamsters, guinea pigs, ferrets, chinchillas, birds such as parrots, canaries, and finches; reptiles such as turtles, lizards, and snakes; and ornamental fish such as goldfish and tropical fish. Additionally, for example, the livestock may include, but are not limited to, cattle, pigs, horses, sheep, goats, chickens, ducks, turkeys, and camels. In addition, for example, the experimental animals may include, but are not limited to, mice, rats, guinea pigs, rabbits, beagle dogs, and primates.
[0191]
[0192] Another aspect provides an anti-aging kit for animals comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof.
[0193] In one embodiment, the first active substance and the second active substance may be provided in the form of a single veterinary kit or each packaged in separate containers. The veterinary kit may include together an injectable container containing the first active substance (e.g., a vial, ampoule, pre-filled syringe, or infusion bag) and a feed formulation container containing the second active substance (e.g., a powder pouch, pellet container, granule container, or liquid container).
[0194] In one embodiment, the animal may refer to livestock, companion animals, laboratory animals, or other non-human animals. The definitions of “livestock,” “companion animals,” “laboratory animals,” etc. are as described above.
[0195] In one embodiment, the kit may be configured for veterinary application. Specifically, the animal kit may be intended for prescription and administration by a veterinarian or animal-related professional and may further include instructions regarding dosage, method of administration, and administration schedule for companion animals, livestock, or laboratory animals. The instructions may include, but are not limited to, specific methods of use regarding parenteral administration of the first active substance (e.g., intravenous injection or intravenous drip infusion) and oral administration of the second active substance.
[0196]
[0197] The terms and methods, etc. described for the above inventions apply equally among the inventions.
[0198] An anti-aging composition according to one embodiment of the present invention can exhibit effects such as improving muscle strength and motor function deteriorated with aging, restoring immune function through an increase in the ratio of natural killer (NK) cells, and improving intestinal function through the restoration of intestinal stem cell marker expression and the suppression of inflammation. In particular, it can be usefully utilized for the prevention, improvement, or treatment of various aging-related diseases, including sarcopenia-related diseases, aging-related immune function decline diseases, and intestinal function decline-related diseases.
[0199] Figure 1 is a schematic illustration of a fusion protein of one embodiment of the present invention.
[0200] Figure 2 is a graph showing the change in forelimb grip strength following the administration of GIB-7 and GI-102 alone or in combination in aging mice, the left graph is a bar graph showing the baseline grip strength of each group before administration, and the right graph is a line graph showing the change in grip strength measured at 0, 1, and 2 weeks after the start of administration.
[0201] Figures 3a and 3b show the results of the analysis of the ratio of NK cells in PBMCs in each mouse group: Figure 3a is a dot plot showing the ratio of NK cells (NK-1.1+, TCRβ-) in PBMCs for each mouse individual in each group analyzed by flow cytometry, and Figure 3b is a bar graph showing the quantified ratio of NK cells in PBMCs for each group.
[0202] Figures 4a and 4b show changes in intestinal length following the administration of GIB-7 and GI-102 alone or in combination in aging mice: Figure 4a is a photograph of the intestines extracted from mice of each group after the end of administration, taken with a scale bar, and Figure 4b is a bar graph showing the total intestinal length, small intestine length, and large intestine length of each group quantified.
[0203] Figure 5 is a bar graph showing the relative expression levels of stem cell marker (Lgr5) and inflammatory cytokine (IL-6, IL-1β) genes following the administration of GIB-7 and GI-102 alone or in combination in the small intestine of aging mice.
[0204] Figure 6 is a bar graph showing the relative expression levels of stem cell marker (Lgr5) and Wnt signaling-related gene (Wnt3) following the administration of GIB-7 and GI-102 alone or in combination in the crypts of the small intestine of aging mice (*p<0.05, **p<0.01).
[0205] Figure 7 is a line graph showing the percentage change from baseline in knee force extension strength (Knee Force Extension R / L), hand grip strength (Hand Grip R / L), and 6-minute walk test (6MWT) for 8 weeks after combined administration of GIB-7 and GI-102 in aging clinical subjects.
[0206] Figure 8 shows the number of lymphocytes (NK and non-NK) and CD16 NK cells (CD56) before and after (W0, W1) co-administration of GIB-7 and GI-102 in aging clinical subjects. bright and CD56 dim This is a bar graph showing the change in ) and NK / Treg ratio.
[0207] Figure 9 shows CD56 using CD16 and CD56 markers at time points before (W0, Day 1) and 1 week after (W1, Day 8) co-administration of GIB-7 and GI-102 in aging clinical subjects. bright NK cells and CD56 dim This is a dot plot analyzing the distribution of NK cells.
[0208] Preferred embodiments are presented below to aid in understanding the present invention. However, the following embodiments are provided merely to facilitate a better understanding of the invention and do not limit the scope of the invention. Since the embodiments are subject to various modifications, they are not limited to the embodiments disclosed below but can be implemented in various forms.
[0209]
[0210] Example 1. Preparation of Fusion Protein
[0211] The fusion protein (GI-102) was prepared using the method described in Korean Patent Application No. 10-2021-0035517. The entirety of said document is incorporated herein by reference.
[0212] Briefly, GI-102 was prepared in the form of a homodimer in which two molecules of a fusion protein monomer, comprising the extracellular domain or a fragment thereof of the CD80 protein, the IgG4 Fc domain, and an IL-2 variant (hIL2v3), were joined by a disulfide bond. Specifically, an expression vector containing the gene encoding the fusion protein was prepared, transfected into mammalian cells, cultured, and purified using Protein A affinity chromatography to obtain the fusion protein dimer.
[0213] The above GI-102 (fusion protein) has a structure in which the TPA signal sequence, CD80 domain, hinge sequence, IgG4 Fc domain, G4S linker, and IL-2 variant (hIL2v3) are connected in order from the N-terminus, and the composition of each domain is as follows.
[0214] The TPA signal sequence is a sequence that induces protein secretion and includes the amino acid sequence of SEQ ID NO. 1, the CD80 protein fragment includes the amino acid sequence of SEQ ID NO. 3, the hinge sequence includes the amino acid sequence of SEQ ID NO. 4, the IgG4 Fc domain includes the amino acid sequence of SEQ ID NO. 6, the G4S linker includes the amino acid sequence of SEQ ID NO. 7, and the IL-2 variant includes the amino acid sequence of SEQ ID NO. 10.
[0215] The amino acid sequence of GI-102 (CD80-IgG4 Fc-IL2v3) according to the above embodiment is shown as SEQ ID NO. 12.
[0216] The IL-2 variant (hIL2v3) included in the above GI-102 is a form in which the 38th (R38A), 42nd (F42A), and 61st (E61R) amino acids in the amino acid sequence of wild-type IL-2 (SEQ No. 8) are substituted. The above IL-2 variant has reduced binding affinity to the IL-2 receptor α subunit (IL-2Rα) compared to wild-type IL-2, thereby inhibiting preferential signaling to regulatory T cells (Treg), while signaling through the IL-2 receptor β subunit (IL-2Rβ) is maintained, which can induce activation and proliferation of NK cells and CD8+ T cells.
[0217]
[0218] Example 2. Isolation and Identification of Lactobacillus fermentum and Lactobacillus plantarum strains
[0219] The isolation and identification of Lactobacillus fermentum strains GB102 and GB103 and Lactobacillus plantarum strain GB104 were performed using the method described in Korean Patent Application No. 10-2022-0080568. The entirety of the said document is incorporated herein by reference.
[0220] Briefly, strains GB102, GB103, and GB104 were isolated from vaginal samples of healthy women who visited the hospital for health checkups. First, vaginal samples were collected using a cotton swab and inoculated onto Rogosa SL (MRS) plates, which were then cultured in an anaerobic chamber at 37°C for 48 hours. Once bacterial colonies grew, single colonies were subcultured onto new MRS plates for pure isolation. After pure isolation, the strains were cultured using MRS medium. Next, among the cultured strains, Lactobacillus fermentum GB102 and GB103 strains and Lactobacillus plantarum GB104 strains, which exhibited low cytotoxicity and an inhibitory effect on adipocyte accumulation, were finally selected. To identify the above-mentioned final selected strains, the 16S rRNA gene sequences obtained by PCR using primers targeting the 16S rRNA gene were analyzed using the Sanger sequencing method, and the 16S rRNA sequences of Lactobacillus fermentum GB102, GB103, and Lactobacillus plantarum GB104 were denoted as sequence numbers 13, 14, and 15, respectively. In addition, Average Nucleotide Identity (ANI) analysis was additionally performed on strains GB102 and GB103 to confirm that they belong to the species Lactobacillus fermentum, and strain GB104 was confirmed to belong to Lactobacillus plantarum through ANI analysis.
[0221] The inventors named strains GB102 and GB103 "Lactobacillus fermentum" GB102 (Deposit No.: KCTC 14105BP) and "Lactobacillus fermentum" GB103 (Deposit No.: KCTC 14106BP), respectively, and named strain GB104 "Lactobacillus plantarum" GB104 (Deposit No.: KCTC 14107BP), and deposited them, respectively, at the Korean Collection for Type Cultures (KCTC) located at the Korea Research Institute of Biotechnology and Bioengineering on January 14, 2020.
[0222] In addition, Lactobacillus fermentum was changed to LimosiLactobacillus fermentum and Lactobacillus plantarum was changed to Lactiplantibacillus plantarum, respectively, and in the following examples, the existing strain names and the changed strain names are described interchangeably.
[0223]
[0224] Experimental Example 1. Confirmation of muscle strength improvement effects following the administration of GIB-7 and GI-102 alone or in combination in aging mice
[0225] We wanted to determine whether the muscle strength of mice degraded by aging improves when GIB-7 and GI-102 are administered alone or in combination. To this end, young mice and aged mice were administered GIB-7 and GI-102 alone or in combination, respectively, and the effect of improving muscle strength was evaluated by measuring changes in grip strength over a certain period.
[0226] Specifically, 6-week-old young mice and 14-15-month-old aged C57BL / 6 male mice were used as experimental animals. As a control group, PBS was administered orally daily to the young mouse group (G1; Young) and the aged mouse group (G2; Old), and PBS was injected subcutaneously once a week, respectively.
[0227] Experimental group 1 (G3; Old+GIB-7) was orally administered GIB-7 daily, and 200 μL of PBS was injected subcutaneously once a week as a solvent control for GI-102. The GIB-7 consists of a mixed strain including Lactobacillus fermentum GB102 and GB103 strains (accession numbers KCTC 14105BP, KCTC 14106BP) and Lactobacillus plantarum GB104 strain (accession number KCTC 14107BP), red ginseng containing ginsenosides Rg1, Rb1, and Rg3, and vitamin B2. In addition, Bifidobacterium animalis subsp. lactis and Lactobacillus acidophilus were included to maintain guaranteed bacterial counts. GIB-7 was 1 × 10⁶ per mouse. 9 The substance was administered by suspending it in 300 μL of PBS to achieve a CFU dose. Experimental group 2 (G4; Old+GI-102) received GI-102 via subcutaneous injection at a dose of 0.5 mg / kg once a week and oral administration of PBS daily. Experimental group 3 (G5; Old+GIB-7+GI-102) received GIB-7 and GI-102 in combination under the same conditions as above. Each group consisted of 6 mice, and the detailed experimental conditions are summarized in Table 1.
[0228] Group Age Administered Substance (Oral / Subcutaneous) Control Group 1G1 Young PBS / PBS Control Group 2G2 Old PBS / PBS Experimental Group 1G3 Old GIB-7 / PBS Experimental Group 2G4 Old PBS / GI-102 Experimental Group 3G5 Old GIB-7 / GI-102
[0229] To evaluate changes in muscle strength following the administration of GIB-7 and GI-102 alone or in combination in aging mice, the forelimb grip strength of each group was measured using a mouse grip strength tester at 0 weeks before administration, and at 1 and 2 weeks after administration. Grip strength measurement was performed by inducing the mouse to grasp the wire of the tester with its forelimb and recording the maximum force the mouse pulled, and the measurement results are presented in Figure 2. Figure 2 is a graph showing the changes in forelimb grip strength following the administration of GIB-7 and GI-102 alone or in combination in aging mice; the graph on the left shows the baseline grip strength of each group before administration as a bar graph, and the graph on the right shows the changes in grip strength measured at 0, 1, and 2 weeks after administration as a line graph.
[0230] As shown in Figure 2, a tendency for increased grip strength was observed in the GIB-7 monotherapy group (G3) and the GI-102 monotherapy group (G4) compared to the aging control group (G2), and the pattern of improvement was more clearly confirmed at the 2-week mark. In particular, in the group administered with both GIB-7 and GI-102 (G5), a more significant increase in grip strength was observed than in the monotherapy groups (G3, G4), and a rapid recovery pattern was observed starting from the 1-week mark, with the highest grip strength value observed at the 2-week mark.
[0231] These results indicate that the combined administration of GIB-7 and GI-102 effectively improves muscle strength reduced by aging and has a useful effect in alleviating age-related decline in muscle function. In particular, given that a superior improvement in grip strength was observed in the combination group compared to the monotherapy group, this combination treatment suggests that it can be usefully utilized for the prevention, improvement, or treatment of muscle loss or decline in muscle function caused by aging.
[0232]
[0233] Experimental Example 2. Confirmation of increased NK cell ratio in PBMCs following administration of GIB-7 and GI-102 alone or in combination in aging mice
[0234] We intended to determine the effect of administering GIB-7 and GI-102 alone or in combination on the immune cell composition of aging mice, particularly the proportion of natural killer (NK) cells. To this end, after administering the test substances to each control group and experimental group in the same manner as in Example 1, peripheral blood mononuclear cells (PBMCs) were isolated and the change in the proportion of NK cells was analyzed.
[0235] Specifically, a small amount of orbital blood was collected from mice in each group 7 days after the start of administration, and PBMCs were isolated using this. The isolated PBMCs were stained with fluorescently labeled antibodies capable of distinguishing immune cell subtypes, including NK cells, and then analyzed by flow cytometry using a FACSymphony A3 instrument. The antibodies used were anti-NK-1.1-APC / Cyanine7 (Biolegend, Cat. no 108724), anti-TCRβ-FITC (Biolegend, Cat. no 109206), anti-CD45-BV711 (Biolegend, Cat. no 103147), and Fixable Viability Dye eFluor™506 (eBioscience, Cat. no 65-0866-14), and the results of the analysis of the NK cell ratio in PBMCs are shown in Figure 2.
[0236] Figures 3a and 3b show the analysis results of the ratio of NK cells within PBMCs in each mouse group:
[0237] Figure 3a is a dot plot showing the ratio of NK cells (NK-1.1+, TCRβ-) in PBMCs for each mouse individual in each group analyzed by flow cytometry, and Figure 3b is a bar graph showing the quantified ratio of NK cells in PBMCs for each group.
[0238] As shown in Figures 3a and 3b, the proportion of NK cells in PBMCs in the young mouse control group (G1) was found to be 5.03%, whereas in the aging mouse control group (G2), it decreased to 2.15%, indicating that the proportion of NK cells in the peripheral immune system significantly decreases with aging.
[0239] In the group administered GIB-7 alone (G3), levels similar to those of the aging control group (G2) were maintained, and no significant increase was observed; however, in the group administered GI-102 alone (G4), the NK cell ratio increased significantly to 14.61%, which is approximately 6.8 times higher than that of the aging control group (G2). Furthermore, in the group administered GIB-7 and GI-102 in combination (G5), the NK cell ratio was 19.80%, confirming a higher level of increase than that of the group administered GI-102 alone (G4). These results demonstrate that GI-102 has a significant effect in restoring the NK cell ratio reduced by aging, and that this effect is further enhanced when administered in combination with GIB-7. This implies that combined treatment with GIB-7 and GI-102 can more effectively improve the decline in immune function associated with aging, particularly the decline in NK cell-based innate immune function.
[0240] From the above results, it was confirmed that the combined administration of GIB-7 and GI-102 effectively increased the reduced ratio of NK cells within PBMCs in aging mice and exhibited a superior immune-enhancing effect compared to monotherapy. Therefore, this suggests that the combined treatment can be usefully utilized for the prevention, improvement, or treatment of aging-related decline in immune function.
[0241]
[0242] Experimental Example 3. Confirmation of the effect of administering GIB-7 and GI-102 alone or in combination to improve the increase in intestinal length in aging mice
[0243] To confirm the effect of combined administration of GIB-7 and GI-102 on increased intestinal length in aged mice, changes in intestinal length were evaluated after administering them alone or in combination for 7 weeks using high-aged mice.
[0244] Specifically, 14.5-week and 17.5-month-old male C57BL / 6Rj mice (Janvier Labs) were used as experimental animals. As controls, the young mouse group (G1; Young) and the aged mouse group (G2; Old) were each administered PBS orally daily and subcutaneously once a week, respectively.
[0245] Experimental group 1 (G3; Old+GIB-7) was orally administered GIB-7 daily, and 200 μL of PBS was injected subcutaneously once a week as a solvent control for GI-102. The GIB-7 consists of a mixed strain including Lactobacillus fermentum GB102 and GB103 strains (accession numbers KCTC 14105BP, KCTC 14106BP) and Lactobacillus plantarum GB104 strain (accession number KCTC 14107BP), red ginseng containing ginsenosides Rg1, Rb1, and Rg3, and vitamin B2. In addition, Bifidobacterium animalis subsp. lactis and Lactobacillus acidophilus were included to maintain guaranteed bacterial counts. GIB-7 was 1 × 10⁶ per mouse. 9 The substance was administered by suspending it in 300 μL of PBS to achieve a CFU dose. Experimental group 2 (G4; Old+GI-102) received GI-102 via subcutaneous injection at a dose of 0.5 mg / kg once a week and oral administration of PBS daily. Experimental group 3 (G5; Old+GIB-7+GI-102) received GIB-7 and GI-102 in combination under the same conditions as above. Each group consisted of 10 mice, and detailed experimental conditions are shown in Table 2.
[0246] Group Age Administered Substance (Oral / Subcutaneous) Control Group 1 G1 Young (14.5-wks) PBS / PBS Control Group 2 G2 Old (17.5 months) PBS / PBS Experimental Group 1 G3 Old (17.5 months) GIB-7 / PBS Experimental Group 2 G4 Old (17.5 months) PBS / GI-10 2 Experimental Group 3 G5 Old (17.5 months) GIB-7 / GI-102
[0247] To determine changes in intestinal length following the administration of GIB-7 and GI-102 alone or in combination in aged mice, the intestines of mice from each group were excised from the stomach to the anus, surrounding tissues were removed, and the intestines were spread out on a necrosis plate. Subsequently, the lengths were measured using ImageJ software (version 1.53a, NIH, USA) with images captured with a scale. The small intestine was defined as the length from the pylorus of the stomach to the entrance of the cecum, and the large intestine as the length from the exit of the cecum to the anus; the results of these measurements for total intestinal length are shown in Figures 4a and 4b. Figures 4a and 4b illustrate the changes in intestinal length following the administration of GIB-7 and GI-102 alone or in combination in aged mice:
[0248] Figure 4a is a photograph of the intestines extracted from mice of each group after administration, along with a scale bar, and Figure 4b is a bar graph showing the total intestine length, small intestine length, and large intestine length of each group quantified.
[0249] As shown in Figures 4a and 4b, the total intestinal length of the young mouse control group (G1) was 39.50 cm on average, whereas in the aged mouse control group (G2), it increased to 44.21 cm on average, confirming a trend of significantly increasing intestinal length with aging. Meanwhile, no significant change was observed in the GIB-7 monotherapy group (G3) and the GI-102 monotherapy group (G4) compared to the aged control group (G2). On the other hand, in the group administered GIB-7 and GI-102 in combination (G5), the total intestinal length decreased to 40.60 cm on average, indicating that the increase in intestinal length caused by aging was significantly alleviated.
[0250] Additionally, analysis of the lengths of the small and large intestines separately confirmed that aging increases the length of both the small and large intestines. However, the combined administration of GIB-7 and GI-102 did not have a significant effect on the length of the large intestine, whereas it showed a tendency to selectively mitigate the increase in small intestine length, restoring it to a level close to that of young mice.
[0251] These results suggest that the increase in intestinal length due to aging, particularly the increase in small intestine length, can be interpreted as one of the morphological changes associated with reduced intestinal homeostasis, and that the combined administration of GIB-7 and GI-102 has the effect of significantly reducing these changes and restoring them to a near-normal range. In particular, given that no distinct improvement was observed in the monotherapy group while a more significant reduction was confirmed in the combination therapy group, it suggests that the combined treatment of GIB-7 and GI-102 may exhibit a synergistic effect in improving structural and functional abnormalities of the intestine caused by aging.
[0252]
[0253] Experimental Example 4. Analysis of changes in stem cell and inflammation-related gene expression following administration of GIB-7 and GI-102 alone or in combination in the small intestine of aging mice
[0254] Changes in stem cell and inflammation-related gene expression following the administration of GIB-7 and GI-102 alone or in combination in the small intestine of aged mice were analyzed.
[0255] Specifically, approximately 2 cm of the ileum of the small intestine was excised from the mice of each group in Experimental Example 3 that had been blood drawn and euthanized, and RNA was extracted using the easy-BLUE™ Total RNA Extraction Kit (iNtRON Biotechnology). The extracted RNA was synthesized into cDNA using the SuPrimeScript cDNA Synthesis Kit (GeNetBio) and then used for qRT-PCR analysis. qRT-PCR was performed on the QuantStudio™ 3 Real-Time PCR System (Applied Biosystems) using AccuPower® 2X GreenStar™ qPCR Master Mix (BIONEER) and MicroAmp™ Optical 96-Well Reaction Plate (Applied Biosystems) according to the manufacturer's manual. The primer set used for the analysis is shown in Table 3.
[0256] GenesForwordSequenceNumberReverseSequenceNumberLgr5CGGGACCTTGAAGATTTCCT16GATTCGGATCAGCCAGCTAC17IL-6CCCCAATTTCCAATGCTCTCC18CGCACTAGGTTTGCCGAGTA19IL-1βAGGCTCCGAGATGAACAACAAA20GTGCCGTCTTTCATTACACAGGA21
[0257] Gapdh was used as an internal control for the quantification of gene expression, and 2 -△△CtRelative gene expression was analyzed using a method, and the results are shown in Figure 5. Figure 5 is a bar graph showing the relative expression levels of stem cell marker (Lgr5) and inflammatory cytokine (IL-6, IL-1β) genes following the administration of GIB-7 and GI-102 alone or in combination in the small intestine of aging mice.
[0258] As shown in Figure 5, in the group administered with GIB-7 and GI-102 (G5), the expression of the Lgr5 gene, an intestinal epithelial stem cell marker, was significantly increased by about 1.9 times compared to the aging mouse control group (G2). On the other hand, the expression of inflammatory cytokine genes IL-6 and IL-1β increased in the aging mouse control group (G2) compared to the young mouse control group (G1), but in the group administered with GIB-7 and GI-102 (G5), it was significantly decreased to a level close to that of the young mouse control group (G1).
[0259] These results indicate that the combined administration of GIB-7 and GI-102 has the effect of improving intestinal tissue homeostasis by restoring molecular markers related to intestinal epithelial regeneration that have deteriorated with aging, and simultaneously suppressing the expression of inflammatory cytokines. Furthermore, these molecular biological changes are consistent with morphological improvements, such as the normalization of small intestine length, which supports the effectiveness of the combined administration in improving aging-related intestinal tissue abnormalities.
[0260]
[0261] Experimental Example 5. Analysis of changes in intestinal stem cell-related gene expression following administration of GIB-7 and GI-102 alone or in combination in aging mouse crypts
[0262] We isolated the crypt (depressed structure between intestinal villi) of the small intestine, where intestinal stem cells are concentrated, and analyzed changes in the expression of intestinal stem cell markers and stem cell maintenance-related genes following the administration of GIB-7 and GI-102 alone or in combination.
[0263] Specifically, the small intestines were excised from the mice of each group in Experimental Example 3 that had been blood drawn and euthanized. The contents were removed by making a longitudinal incision, and the mucosa and villi were removed using a cover glass before washing. The washed small intestines were cut into lengths of approximately 1 cm, transferred to a 50 mL centrifuge tube containing 25 mL of cold PBS, and washed by vigorously shaking; this washing process was repeated twice. Subsequently, the small intestine tissue was immersed in DPBS containing 1 mM EDTA and incubated on ice for 30 minutes while being turned over at 10-minute intervals. After the reaction, the tissue was retrieved, washed three times with cold PBS, and then immersed in DPBS containing 5 mM EDTA for an additional 60 minutes in the same manner. Next, the tissue was transferred to a tube containing 25 mL of cold PBS and vigorously shaken to detach the crypts from the small intestine tissue. The obtained suspension was sequentially filtered using 100 μm and 40 μm cell strainers, and a crypt precipitate was obtained by centrifugation (900 rpm, 3 min). RNA was extracted from the precipitate using the easy-BLUE™ Total RNA Extraction Kit (iNtRON Biotechnology), and cDNA was synthesized using the SuPrimeScript cDNA Synthesis Kit (GeNetBio) for use in qRT-PCR analysis. qRT-PCR was performed on a QuantStudio™ 3 Real-Time PCR System (Applied Biosystems) using AccuPower®2X GreenStar™ qPCR Master Mix (BIONEER) and a MicroAmp™ Optical 96-Well Reaction Plate (Applied Biosystems) according to the manufacturer's manual. The primer set used for the analysis is shown in Table 4.
[0264] GenesForwordSequenceNumberReverseSequenceNumberLgr5CGGGACCTTGAAGATTTCCT16GATTCGGATCAGCCAGCTAC17Wnt3CCCCAATTTCCAATGCTCTCC22CGCACTAGGTTTGCCGAGTA23
[0265] Gapdh was used as an internal control for the quantification of gene expression, and 2 -△△Ct Relative gene expression was analyzed using the method, and the results are shown in Figure 6.
[0266] Figure 6 is a bar graph showing the relative expression levels of stem cell marker (Lgr5) and Wnt signaling-related gene (Wnt3) following the administration of GIB-7 and GI-102 alone or in combination in the crypts of the small intestine of aging mice (*p<0.05, **p<0.01).
[0267] As shown in Figure 6, in the group (G5) administered with GIB-7 and GI-102, the expression of Lgr5, a marker of crypt basal intestinal epithelial stem cells, was significantly increased by about 2 times compared to the aging mouse control group (G2). In addition, the expression of the Wnt3 gene, which is expressed in Panes cells and is involved in maintaining the microenvironment of intestinal epithelial stem cells, was also significantly increased by about 1.9 times compared to the aging mouse control group (G2).
[0268] These results indicate that the combined administration of GIB-7 and GI-102 has the effect of improving the intestinal epithelial regeneration microenvironment, which is degraded with aging, and restoring homeostasis of intestinal tissue by simultaneously increasing the expression of intestinal epithelial stem cell-related molecular markers and stem cell niche-related factors within the small intestine crypt.
[0269]
[0270] Experimental Example 6. Confirmation of improvement in muscle function and immune function following combined administration of GIB-7 and GI-102 in aging clinical subjects
[0271] This experimental example is an initial clinical result derived from a clinical trial in Australia, confirming the trend of effects following combination administration based on preliminary clinical results obtained from a single patient.
[0272]
[0273] 6.1 Confirmation of changes in muscle strength and motor function following concomitant administration of GIB-7 and GI-102
[0274] To determine the effect of combined administration of GIB-7 and GI-102 on muscle strength and motor function in aging clinical subjects, right / left knee extension strength (Knee Force Extension R / L), right / left hand grip strength (Hand Grip R / L), and 6-minute walk test (6MWT) were measured weekly from before the start of combined administration (W0) until 8 weeks after administration (W8), and the percentage change of each indicator relative to baseline was calculated.
[0275] Specifically, according to the 'Protocol' of the clinical trial, the combination therapy was administered by infusing GI-102 at a dose of 0.02 mg / kg twice at 4-week intervals (Q4W) and administering 3 capsules of GIB-7 orally once a day. However, in the preliminary results of the first clinical patient (102-05) in Example 6 of this study, specifically, GI-102 was infused once at a dose of 0.02 mg / kg, and 3 capsules of GIB-7 were administered orally once a day. The data was based on one subject, and right and left knee extension strength (Knee Force Extension R / L) and right and left hand grip strength (Hand Grip R / L) were measured as muscle strength evaluation indices, while the 6-Minute Walk Test (6MWT) was performed as an exercise function evaluation indices. All measurements were expressed as a percentage change (%) compared to before the start of administration (W0), and the results are shown in Fig. 7. All measurements were expressed as a percentage change (%) compared to before the start of administration (W0), and the results are shown in Fig. 7.
[0276] Figure 7 is a line graph showing the percentage change from baseline in knee force extension strength (Knee Force Extension R / L), hand grip strength (Hand Grip R / L), and 6-minute walk test (6MWT) for 8 weeks after combined administration of GIB-7 and GI-102 in aging clinical subjects.
[0277] As shown in Figure 7, after the combined administration of GIB-7 and GI-102, knee force extension strength (Knee Force Extension R / L) began to increase from W2 (Knee Force Extension L decreased briefly in W2 and rebounded from W3), showing high growth rates of approximately 93% and 73%, respectively, compared to baseline at W8. Hand grip strength (Hand Grip R / L) and 6-minute walk test (6MWT) also gradually increased during the administration period, and an improvement of approximately 26–33% compared to baseline was confirmed at W8.
[0278] These results suggest that the combined administration of GIB-7 and GI-102 may have an effect on improving overall muscle function and motor function, including knee extension strength, grip strength, and walking ability, in aging clinical subjects.
[0279]
[0280] 6.2 Confirmation of Changes in Lymphocyte and NK Cell Ratios in Peripheral Blood Following Combined Administration of GIB-7 and GI-102
[0281] To determine the effect of combined administration of GIB-7 and GI-102 on the ratio of lymphocytes and NK cells in the peripheral blood of aging clinical subjects, peripheral blood was collected before the start of administration (W0, Day 1) and one week after administration (W1, Day 8) and lymphocyte and NK cell subtypes were analyzed.
[0282] Specifically, the lymphocyte count (cells / μL), CD16 NK cell count (cells / μL), and NK / Treg ratio were analyzed from collected peripheral blood, and NK cells according to CD56 expression levels CD56 bright and CD56 dim They were classified into subtypes and quantified. In addition, changes in the distribution of NK cell subtypes were analyzed using flow cytometry with CD16 and CD56 markers, and the results are shown in Figures 8 and 9.
[0283] NK cells have strong immunomodulatory functions depending on the CD56 expression level. bright CD56 with strong subtypes and cytotoxic functions dim It is classified into subtypes. It is known that as aging progresses, both subtypes generally show a decrease in numbers and a decline in function, which is considered one of the major causes of the decline in innate immune function associated with aging. Therefore, CD56 bright and CD56 dim Analyzing changes in NK cell subtypes can be an important indicator for evaluating whether the decline in immune function due to aging is improved.
[0284] Figure 8 shows the number of lymphocytes (NK and non-NK) and CD16 NK cells (CD56) before and after (W0, W1) co-administration of GIB-7 and GI-102 in aging clinical subjects. bright and CD56 dim This is a bar graph showing the change in ) and NK / Treg ratio.
[0285] As shown in Figure 8, at the time point 1 week after the combined administration of GIB-7 and GI-102 (W1), the number of lymphocytes excluding NK cells (non-NK) increased only 1.1-fold compared to baseline, while the number of NK cells increased significantly by 2.9-fold. In the case of CD16 NK cells, CD56 bright A-type is 3.6 times, CD56 dim The number of subtypes increased 2.7 times, and the NK / Treg ratio increased 2.7 times from 24.4 to 66.7.
[0286] Figure 9 shows CD56 using CD16 and CD56 markers at time points before (W0, Day 1) and 1 week after (W1, Day 8) co-administration of GIB-7 and GI-102 in aging clinical subjects. bright NK cells and CD56 dim This is a dot plot analyzing the distribution of NK cells.
[0287] As shown in Fig. 9, CD56 in lymphocytes at time 1 week after co-administration (W1) compared to before co-administration of GIB-7 and GI-102 (W0). bright The proportion of NK cells increased from 8.24% to 16.1%, CD56 dim The proportion of NK cells increased from 32.5% to 46.3%, confirming a distinct expansion of distribution across NK cell subtypes.
[0288] These results indicate that the combined administration of GIB-7 and GI-102 significantly increases the number of NK cells and the NK / Treg ratio in peripheral blood of aging clinical subjects, particularly CD56 bright and CD56 dim This means that activation and proliferation are promoted in all NK cell subtypes. This suggests that combined treatment with GIB-7 and GI-102 can effectively improve age-related decline in immune function.
[0289]
[0290] [Consignment Number]
[0291] Depository: Korea Research Institute of Bioscience and Biotechnology
[0292] Trustee Number: KCTC14105BP
[0293] Date of Trust: 20200114
[0294]
[0295]
[0296] Depository: Korea Research Institute of Bioscience and Biotechnology
[0297] Trustee Number: KCTC14106BP
[0298] Date of Trust: 20200114
[0299]
[0300]
[0301] Depository: Korea Research Institute of Bioscience and Biotechnology
[0302] Trustee Number: KCTC14107BP
[0303] Date of Trust: 20200114
[0304]
Claims
1. A combination for anti-aging comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
2. A combination according to claim 1, wherein the second active substance further comprises red ginseng or a vitamin.
3. A combination according to claim 1, wherein the Lactobacillus sp. strain is the Lactobacillus fermentum GB102 strain deposited at KCTC 14105BP, the Lactobacillus fermentum GB103 strain deposited at KCTC 14106BP, or the Lactobacillus plantarum GB104 strain deposited at KCTC 14107BP.
4. A combination according to claim 1, wherein the CD80 protein or a fragment thereof and the IL-2 protein or a variant thereof are combined by a linker.
5. A combination according to claim 1, wherein the IL-2 variant comprises the amino acid sequence of SEQ ID NO.
10.
6. A combination according to claim 1, wherein the fragment of the CD80 protein comprises the amino acid sequence of SEQ ID NO.
3.
7. A combination according to claim 1, wherein the first active substance and the second active substance are separate formulations.
8. A combination according to claim 1, wherein the first active substance is provided as a parenteral formulation and the second active substance is provided as an oral formulation.
9. A combination according to claim 1, wherein the first active substance is provided as a subcutaneous administration formulation or an intravenous administration formulation.
10. A combination according to claim 1, wherein the first active substance and the second active substance are administered simultaneously, sequentially, or in any order.
11. A pharmaceutical product comprising the combination of the products of paragraph 1, administered simultaneously, sequentially, or in any order for an anti-aging effect.
12. A combination according to claim 1, wherein the anti-aging includes the prevention or treatment of one or more diseases selected from the group consisting of diseases related to intestinal dysfunction, diseases related to decreased immune function, and diseases related to sarcopenia.
13. A combination for the prevention or treatment of diseases related to intestinal dysfunction, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
14. A combination according to claim 13, wherein the intestinal dysfunction-related disease is one or more selected from the group consisting of inflammatory bowel disease, irritable bowel syndrome, reduced intestinal epithelial regeneration, intestinal atrophy, leaky gut syndrome, and age-related decline in intestinal function.
15. A combination for the prevention or treatment of age-related immune dysfunction, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
16. A combination according to claim 15, wherein the aging-related immune function decline disease is one or more selected from the group consisting of immunosenescence, natural killer (NK) cell dysfunction, aging-related infection vulnerability, aging-related chronic low-grade inflammation (inflammaging), aging-related cancer surveillance decline, aging-related viral infection, and aging-related vaccine response decline.
17. A combination for the prevention or treatment of sarcopenia-related diseases, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
18. A combination according to claim 17, wherein the sarcopenia-related disease is one or more selected from the group consisting of sarcopenia, senile sarcopenia, atony, muscular atrophy, muscular dystrophy, disuse muscle atrophy, motor neuron disease, inflammatory myopathy, neuromuscular junction disease, endocrine myopathy, muscle degeneration, myositis, amyotrophic lateral sclerosis, myasthenia gravis, myositis, muscle calcification, muscle ossification, and muscle weakness-related diseases.
19. An anti-aging composition comprising a first active substance to be administered in combination with a second active substance, The first active substance comprises a fusion protein comprising CD80 protein or a fragment thereof and IL-2 protein or a variant thereof, and An anti-aging composition wherein the second active substance comprises a Lactobacillus sp. strain, a lysate of the strain, a culture medium, or a mixture thereof.
20. An anti-aging composition comprising a second active substance to be administered in combination with a first active substance, The first active substance comprises a fusion protein comprising CD80 protein or a fragment thereof and IL-2 protein or a variant thereof, and An anti-aging composition wherein the second active substance comprises a Lactobacillus sp. strain, a lysate of the strain, a culture medium, or a mixture thereof.
21. A first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof; a combination therapy kit for anti-aging.
22. A feed composition for anti-aging of animals comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
23. A combination therapy kit for the prevention or treatment of diseases related to impaired intestinal function, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
24. A combination therapy kit for the prevention or treatment of age-related immune dysfunction, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
25. A combination therapy kit for the prevention or treatment of sarcopenia-related diseases, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
26. Use for manufacturing an anti-aging agent comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
27. A method for anti-aging comprising: a step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to an individual in need thereof; and a step of administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
28. Use of the first active substance for co-administration with the second active substance for anti-aging purposes.
29. Use of a second active substance to be administered in combination with a first active substance for anti-aging purposes.
30. Use for manufacturing a drug for the prevention or treatment of diseases related to impaired intestinal function, comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
31. A method for treating a disease related to impaired intestinal function, comprising: a step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to an individual in need thereof; and a step of administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
32. Use of the first active substance to be administered in combination with the second active substance for the prevention or treatment of diseases related to impaired bowel function.
33. Use of a second active substance to be administered in combination with a first active substance for the prevention or treatment of diseases related to impaired bowel function.
34. Use for manufacturing a drug for the prevention or treatment of age-related immune function decline diseases comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
35. A method for treating age-related immune dysfunction, comprising: a step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to an individual in need thereof; and a step of administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
36. Use of the first active substance to be administered in combination with the second active substance for the prevention or treatment of age-related immune function decline.
37. Use of a second active substance to be administered in combination with a first active substance for the prevention or treatment of age-related immune dysfunction.
38. Use for manufacturing a drug for the prevention or treatment of sarcopenia-related diseases comprising: a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof; and a second active substance comprising a Lactobacillus sp. strain, a lysate, a culture medium, or a mixture thereof.
39. A method for treating a sarcopenia-related disease comprising: a step of administering a therapeutically effective amount of a first active substance comprising a fusion protein comprising a CD80 protein or a fragment thereof and an IL-2 protein or a variant thereof to an individual in need thereof; and a step of administering a therapeutically effective amount of a second active substance comprising a Lactobacillus sp. strain, a lysate of said strain, a culture medium, or a mixture thereof to an individual in need thereof.
40. Use of the first active substance for co-administration with the second active substance for the prevention or treatment of sarcopenia-related diseases.
41. Use of a second active substance to be administered in combination with a first active substance for the prevention or treatment of sarcopenia-related diseases.
